On October 14, Liquidia Technologies Inc rose 34.22% in Regular Trading, trading at $36.15 per share, with turnover of $140 million.
The clearest catalyst is an analyst action released the same day: BTIG upgraded Liquidia Technologies Inc to Buy from Neutral and set a $70 price target, providing a fresh bullish signal as the stock extended a sharp rebound.
Recent background has also turned more constructive. Earlier pressure followed Chairman Stephen Bloch's October 5 sale of 235,477 shares at $27.13 through Canaan LP for about $6.4 million, reducing that entity's stake to zero. However, investors have recently refocused on YUTREPIA's commercial momentum and pipeline progress, including FDA Fast Track designation for systemic sclerosis-associated Raynaud's phenomenon. In the second quarter, YUTREPIA net product sales were about $170.4 million, up 31% from the first quarter.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments